The DOI matches its Crossref record; 37 of the 37 references it cites were found in a registry or an index.
Cardiovascular Outcomes in Patients With Primary Aldosteronism After Treatment
Open accessAbstract
BACKGROUND: Experimental and human studies demonstrate that long-term exposure to elevated aldosterone levels results in cardiac and vascular damage. METHODS: We investigated long-term cardiovascular outcomes in patients with primary aldosteronism after surgical or medical treatment. Fifty-four patients with or without evidence of adrenal adenomas were prospectively followed up for a mean of 7.4 years after treatment with adrenalectomy or spironolactone. Patients with primary aldosteronism were compared with patients with essential hypertension and were treated to reach a blood pressure of less than 140/90 mm Hg. The main outcome measure was a combined cardiovascular end point comprising myocardial infarction, stroke, any type of revascularization procedure, and sustained arrhythmias. RESULTS: At baseline, the prevalence of cardiovascular events was greater in primary aldosteronism (35%) than in essential hypertension (11%) (odds ratio, 4.61; 95% confidence interval, 2.38-8.95; P< .001), with odds ratios of 4.93, 4.36, and 2.80 for sustained arrhythmias, cerebrovascular events, and coronary heart disease, respectively. Blood pressure during follow-up was comparable in the primary aldosteronism and essential hypertension groups. Ten patients in the primary aldosteronism group and 19 in the essential hypertension group reached the primary end point (P= .85). Cox analysis indicated that older age and longer duration of hypertension were factors independently associated with the cardiovascular end point. Cardiovascular outcome was comparable in patients with aldosteronism treated with adrenalectomy vs aldosterone antagonists (P= .71). CONCLUSION: Primary aldosteronism is associated with a cardiovascular complication rate out of proportion to blood pressure levels that benefits substantially from surgical and medical treatment in the long term.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Regression Models and Life-Tables
Cox, D. R. (1972) · Journal of the Royal Statistical Society Series B: Statistical Methodology · doi:10.1111/j.2517-6161.1972.tb00899.x · Cited by 39,793
Regression Models and Life-Tables
Cox, D. R. (1992) · Springer Series in Statistics · doi:10.1007/978-1-4612-4380-9_37 · Cited by 26,297
The Effect of Spironolactone on Morbidity and Mortality in Patients with Severe Heart Failure
Pitt, B., Zannad, F., Remme, W. J., Cody, R., Castaigne, A., Perez, A., Palensky, J., & Wittes, J. (1999) · New England Journal of Medicine · doi:10.1056/nejm199909023411001 · Cited by 9,214
Pitt, B., Remme, W., Zannad, F., Neaton, J., Martinez, F., Roniker, B., Bittman, R., Hurley, S., Kleiman, J., & Gatlin, M. (2003) · New England Journal of Medicine · doi:10.1056/nejmoa030207 · Cited by 4,941
Asymptotically Efficient Rank Invariant Test Procedures
Peto, R., & Peto, J. (1972) · Journal of the Royal Statistical Society. Series A (General) · doi:10.2307/2344317 · Cited by 3,393
The Effect of Spironolactone on Morbidity and Mortality in Patients with Severe Heart Failure
PITT, B., ZANNAD, F., REMME, W. J., CODY, R., CASTAIGNE, A., PEREZ, A., PALENSKY, J., & WITTES, J. (2000) · Survey of Anesthesiology · doi:10.1097/00132586-200006000-00059 · Cited by 2,927
Evidence for an increased rate of cardiovascular events in patients with primary aldosteronism
Milliez, P., Girerd, X., Plouin, P.-F., Blacher, J., Safar, M. E., & Mourad, J.-J. (2005) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2005.01.015 · Cited by 1,547
Mulatero (2004) · doi:10.1210/jc.2003-031337 · Cited by 961
Pitt, B., Wj, R., Zannad, F. M., Neaton, J. D., Martínez, F. A., Roniker, B., Bittman, R. M., Hurley, S., Kleiman, J. H., & Gatlin, M. R. (2003) · Cited by 708
Vasodilation to acetylcholine in primary and secondary forms of human hypertension.
Taddei, S., Virdis, A., Mattei, P., & Salvetti, A. (1993) · Hypertension · doi:10.1161/01.hyp.21.6.929 · Cited by 535
Cited by
Funder, J. W., Carey, R. M., Mantero, F., Murad, M. H., Reincke, M., Shibata, H., Stowasser, M., & Young, W. F. (2016) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2015-4061 · Cited by 2,925
Monticone, S., D'Ascenzo, F., Moretti, C., Williams, T. A., Veglio, F., Gaita, F., & Mulatero, P. (2018) · The Lancet Diabetes & Endocrinology · doi:10.1016/s2213-8587(17)30319-4 · Cited by 1,072
Williams, T. A., Lenders, J. W. M., Mulatero, P., Burrello, J., Rottenkolber, M., Adolf, C., Satoh, F., Amar, L., Quinkler, M., Deinum, J., et al. (2017) · The Lancet Diabetes & Endocrinology · doi:10.1016/s2213-8587(17)30135-3 · Cited by 969
Self-citationPrevalence and Clinical Manifestations of Primary Aldosteronism Encountered in Primary Care Practice
Monticone, S., Burrello, J., Tizzani, D., Bertello, C., Viola, A., Buffolo, F., Gabetti, L., Mengozzi, G., Williams, T. A., Rabbia, F., et al. (2017) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2017.01.052 · Cited by 882
Hundemer, G. L., Curhan, G. C., Yozamp, N., Wang, M., & Vaidya, A. (2018) · The Lancet Diabetes & Endocrinology · doi:10.1016/s2213-8587(17)30367-4 · Cited by 677
The Unrecognized Prevalence of Primary Aldosteronism: A Cross-sectional Study
Brown, J. M., Siddiqui, M., Calhoun, D. A., Carey, R. M., Hopkins, P. N., Williams, G. H., & Vaidya, A. (2020) · Annals of Internal Medicine · doi:10.7326/m20-0065 · Cited by 649
Douma, S., Petidis, K., Doumas, M., Papaefthimiou, P., Triantafyllou, A., Kartali, N., Papadopoulos, N., Vogiatzis, K., & Zamboulis, C. (2008) · The Lancet · doi:10.1016/s0140-6736(08)60834-x · Cited by 560
Savard, S., Amar, L., Plouin, P.-F., & Steichen, O. (2013) · Hypertension · doi:10.1161/hypertensionaha.113.01060 · Cited by 505
Long-Term Cardio- and Cerebrovascular Events in Patients With Primary Aldosteronism
Mulatero, P., Monticone, S., Bertello, C., Viola, A., Tizzani, D., Iannaccone, A., Crudo, V., Burrello, J., Milan, A., Rabbia, F., et al. (2013) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2013-2805 · Cited by 415
Käyser, S. C., Dekkers, T., Groenewoud, H. J., van der Wilt, G. J., Carel Bakx, J., van der Wel, M. C., Hermus, A. R., Lenders, J. W., & Deinum, J. (2016) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2016-1472 · Cited by 398
Rossi, G. P., Cesari, M., Cuspidi, C., Maiolino, G., Cicala, M. V., Bisogni, V., Mantero, F., & Pessina, A. C. (2013) · Hypertension · doi:10.1161/hypertensionaha.113.01316 · Cited by 356
Primary Aldosteronism: An Endocrine Society Clinical Practice Guideline
Adler, G. K., Stowasser, M., Correa, R. R., Khan, N., Kline, G., McGowan, M. J., Mulatero, P., Murad, M. H., Touyz, R. M., Vaidya, A., et al. (2025) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/clinem/dgaf284 · Cited by 355
Diagnosis and treatment of primary aldosteronism: practical clinical perspectives
Young, W. F. (2019) · Journal of Internal Medicine · doi:10.1111/joim.12831 · Cited by 325
Vaidya, A., Mulatero, P., Baudrand, R., & Adler, G. K. (2018) · Endocrine Reviews · doi:10.1210/er.2018-00139 · Cited by 299
Steroid metabolome analysis reveals prevalent glucocorticoid excess in primary aldosteronism
Arlt, W., Lang, K., Sitch, A. J., Dietz, A. S., Rhayem, Y., Bancos, I., Feuchtinger, A., Chortis, V., Gilligan, L. C., Ludwig, P., et al. (2017) · JCI Insight · doi:10.1172/jci.insight.93136 · Cited by 281
Parthasarathy, H. K., Ménard, J., White, W. B., Young, W. F., Williams, G. H., Williams, B., Ruilope, L. M., McInnes, G. T., Connell, J. M., & MacDonald, T. M. (2011) · Journal of Hypertension · doi:10.1097/hjh.0b013e3283455ca5 · Cited by 281
Observational Study Mortality in Treated Primary Aldosteronism: The German Conn's Registry
Reincke, M., Fischer, E., Gerum, S., Merkle, K., Schulz, S., Pallauf, A., Quinkler, M., Hanslik, G., Lang, K., Hahner, S., et al. (2012) · Hypertension · doi:10.1161/hypertensionaha.112.197111 · Cited by 278
Born-Frontsberg, E., Reincke, M., Rump, L. C., Hahner, S., Diederich, S., Lorenz, R., Allolio, B., Seufert, J., Schirpenbach, C., Beuschlein, F., et al. (2009) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2008-2116 · Cited by 261
The Spectrum of Subclinical Primary Aldosteronism and Incident Hypertension: A Cohort Study
Brown, J. M., Robinson-Cohen, C., Luque-Fernandez, M. A., Allison, M. A., Baudrand, R., Ix, J. H., Kestenbaum, B., de Boer, I. H., & Vaidya, A. (2017) · Annals of Internal Medicine · doi:10.7326/m17-0882 · Cited by 221
Tomaschitz, A., Pilz, S., Ritz, E., Meinitzer, A., Boehm, B. O., & Marz, W. (2010) · European Heart Journal · doi:10.1093/eurheartj/ehq019 · Cited by 171
Clinical characteristics of somatic mutations in Chinese patients with aldosterone-producing adenoma
Zheng, F.-F., Zhu, L.-M., Nie, A.-F., Li, X.-Y., Lin, J.-R., Zhang, K., Chen, J., Zhou, W.-L., Shen, Z.-J., Zhu, Y.-C., et al. (2015) · Hypertension · doi:10.1161/hypertensionaha.114.03346 · Cited by 151
Irvin, M. R., Booth, J. N., Shimbo, D., Lackland, D. T., Oparil, S., Howard, G., Safford, M. M., Muntner, P., & Calhoun, D. A. (2014) · Journal of the American Society of Hypertension · doi:10.1016/j.jash.2014.03.003 · Cited by 146
Steroid Metabolome Analysis in Disorders of Adrenal Steroid Biosynthesis and Metabolism
Storbeck, K.-H., Schiffer, L., Baranowski, E. S., Chortis, V., Prete, A., Barnard, L., Gilligan, L. C., Taylor, A. E., Idkowiak, J., Arlt, W., et al. (2019) · Endocrine Reviews · doi:10.1210/er.2018-00262 · Cited by 141
(2022) · PubMed Central · doi:10.6515/acs.202205_38(3).20220321a · Cited by 117
Laboratory challenges in primary aldosteronism screening and diagnosis
Rehan, M., Raizman, J. E., Cavalier, E., Don-Wauchope, A. C., & Holmes, D. T. (2015) · Clinical Biochemistry · doi:10.1016/j.clinbiochem.2015.01.003 · Cited by 89
Aldosterone excess impairs first phase insulin secretion in primary aldosteronism
Fischer, E., Adolf, C., Pallauf, A., Then, C., Bidlingmaier, M., Beuschlein, F., Seissler, J., & Reincke, M. (2013) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2012-3934 · Cited by 88
Reversible Sympathetic Overactivity in Hypertensive Patients with Primary Aldosteronism
Kontak, A. C., Wang, Z., Arbique, D., Adams-Huet, B., Auchus, R. J., Nesbitt, S. D., Victor, R. G., & Vongpatanasin, W. (2010) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2010-0823 · Cited by 71
Samnani, S., Cenzer, I., Kline, G. A., Lee, S. J., Hundemer, G. L., McClurg, C., Pasieka, J. L., Boscardin, W. J., Ronksley, P. E., & Leung, A. A. (2024) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/clinem/dgad654 · Cited by 50
Hennings, J., Sundin, A., Hägg, A., & Hellman, P. (2010) · Langenbeck s Archives of Surgery · doi:10.1007/s00423-010-0681-7 · Cited by 44
Gorenek, B., Boriani, G., Dan, G.-A., Fauchier, L., Fenelon, G., Huang, H., Kudaiberdieva, G., Lip, G. Y. H., Mahajan, R., Potpara, T., et al. (2018) · EP Europace · doi:10.1093/europace/euy051 · Cited by 43
Fischer, E., Hannemann, A., Rettig, R., Lieb, W., Nauck, M., Pallauf, A., Bildingmaier, M., Beuschlein, F., Wallaschofski, H., & Reincke, M. (2014) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2013-3214 · Cited by 37
Tsurutani, Y., Sugisawa, C., Ishida, A., Inoue, K., Saito, J., Omura, M., Nagasaka, S., & Nishikawa, T. (2017) · Endocrine Journal · doi:10.1507/endocrj.ej16-0500 · Cited by 32
Primary Aldosteronism: Cardiovascular Outcomes Pre- and Post-treatment
Hundemer, G. L. (2019) · Current Cardiology Reports · doi:10.1007/s11886-019-1185-x · Cited by 27
Asbach, E., Bekeran, M., König, A., Lang, K., Hanslik, G., Treitl, M., Ladurner, R., Bidlingmaier, M., Beuschlein, F., Quinkler, M., et al. (2020) · Experimental and Clinical Endocrinology & Diabetes · doi:10.1055/a-1027-6472 · Cited by 25
“Compared to essential hypertension, PA is associated with a higher prevalence of cardiovascular and renal complications [3, 4].”
Background
Metadata
- Authors
- Catena, C.
- Venue
- Archives of Internal Medicine
- Publisher
- American Medical Association (AMA)
- Published
- 2008-01-14
- Volume
- 168
- Issue
- 1
- Pages
- 80
- ISSN
- 0003-9926 (ISSN-L)
- OpenAlex
- W2032582841
- Cited by
- 565
- References
- 37
- FWCI
- 18.95
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.